Dehydroepiandrosterone (DHEA) and its sulfate ester are the most abundant steroids in humans. DHEA levels fall with age in men and women, reaching values sometimes as low as 10%–20% of those encountered in young individuals. This age-related decrease suggests an “adrenopause” phenomenon. Studies point toward several potential roles of DHEA, mainly through its hormonal end products, making this decline clinically relevant. Unfortunately, even if positive effects of DHEA on muscle, bone, cardiovascular disease, and sexual function seem rather robust, extremely few studies are large enough and/or long enough for conclusions regarding its effects on aging. Moreover, because it has been publically presented as a “fountain of youth” equivalent, over-the-counter preparations lacking pharmacokinetic and pharmacodynamic data are widely used worldwide. Conceptually, supplementing a pre-hormone is extremely interesting, because it would permit the human organism to adequately use it throughout long periods, increasing or decreasing end products according to his needs. Nevertheless, data on the safety profile of long-term DHEA supplementation are still lacking. In this article, we examine the potential relation between low DHEA levels and well-known age-related diseases, such as sarcopenia, osteoporosis, dementia, sexual disorders, and cardiovascular disease. We also review risks and benefits of existing protocols of DHEA supplementation.
GenazzaniAD, LanzoniC, GenazzaniAR. Might DHEA be considered a beneficial replacement therapy in the elderly?Drugs Aging, 2007; 24:173–185.
7.
KushnirMM, BlamiresT, RockwoodAL, RobertsWL, YueB, ErdoganE, BunkerAM, MeikleAW. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem, 2010; 56:1138–1147.
8.
KaufmanJM, VermeulenA. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev, 2005; 26:833–876.
9.
BaulieuEE, ThomasG, LegrainS, LahlouN, RogerM, DebuireB, FaucounauV, GirardL, HervyMP, LatourF, LeaudMC, MokraneA, Pitti-FerrandiH, TrivalleC, de LacharrièreO, NouveauS, Rakoto-ArisonB, SouberbielleJC, RaisonJ, Le BoucY, RaynaudA, GirerdX, ForetteF. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA, 2000; 97:4279–4284.
10.
LebrunCE, van der SchouwYT, de JongFH, PolsHA, GrobbeeDE, LambertsSW. Relations between body composition, functional and hormonal parameters and quality of life in healthy postmenopausal women. Maturitas, 2006; 55:82–92.
11.
MoralesAJ, HaubrichRH, HwangJY, AsakuraH, YenSS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol, 1998; 49:421–432.
12.
ArltW, JustlHG, CalliesF, ReinckeM, HüblerD, OettelM, ErnstM, SchulteHM, AllolioB. Oral dehydroepiandrosterone for adrenal androgen replacement: Pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab, 1998; 83:1928–1934.
13.
ArltW, HaasJ, CalliesF, ReinckeM, HüblerD, OettelM, ErnstM, SchulteHM, AllolioB. Biotransformation of oral dehydroepiandrosterone in elderly men: Significant increase in circulating estrogens. J Clin Endocrinol Metab, 1999; 84:2170–2176.
14.
MoralesAJ, NolanJJ, NelsonJC, YenSS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab, 1994; 78:1360–1367.
15.
LiuD, DillonJS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3)J Biol Chem, 2002; 277:21379–21388.
16.
LiuD, DillonJS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: Evidence for a cell surface receptor. Steroids, 2004; 69:279–289.
17.
SimonciniT, MannellaP, FornariL, VaroneG, CarusoA, GenazzaniAR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology, 2003; 144:3449–3455.
18.
TraishAM, KangHP, SaadF, GuayAT. Dehydroepiandrosterone (DHEA) a precursor steroid or an active hormone in human physiology. J Sex Med, 2011; 8:2960–2982.
19.
SandersAB. Changing clinical practice in geriatric emergency medicine. Acad Emerg Med, 1999; 6:1189–1193.
20.
LippunerK, JohanssonH, KanisJA, RizzoliR. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int, 2009; 20:1131–1140.
21.
Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc, 2001; 49:664–672.
22.
JanssenI, RossR. Linking age-related changes in skeletal muscle mass and composition with metabolism and disease. J Nutr Health Aging, 2005; 9:408–419.
23.
YenSS, MoralesAJ, KhorramO. Replacement of DHEA in aging men and women. Potential remedial effects. Ann NY Acad Sci, 1995; 774:128–142.
24.
ValentiG, DentiL, MaggioM, CedaG, VolpatoS, BandinelliS, CeresiniG, CappolaA, GuralnikJM, FerrucciL. Effect of DHEAS on skeletal muscle over the life span: The InCHIANTI study. J Gerontol Ser A, Biol Sci Med Sci, 2004; 59:466–472.
25.
KostkaT, ArsacLM, PatricotMC, BerthouzeSE, LacourJR, BonnefoyM. Leg extensor power and dehydroepiandrosterone sulfate, insulin-like growth factor-I and testosterone in healthy active elderly people. Eur J Appl Physiol, 2000; 82:83–90.
26.
RavagliaG, FortiP, MaioliF, BoschiF, CicognaniA, BernardiM, PratelliL, PizzoferratoA, PorcuS, GasbarriniG. Determinants of functional status in healthy Italian nonagenarians and centenarians: A comprehensive functional assessment by the instruments of geriatric practice. J Am Geriatr Soc, 1997; 45:1196–1202.
27.
Bischoff-FerrariHA, OravEJ, Dawson-HughesB. Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporos Int, 2008; 19:1307–1314.
28.
VillarealDT, HolloszyJO, KohrtWM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol, 2000; 53:561–568.
29.
Kalman DSCC, SwainMA, TorinaGC, ShiQ. A randomized, double-blind, placebo-controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy over- weight adults. Curr Ther Res, 2000; 61:435–442.
30.
VillarealDT, HolloszyJO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA, 2004; 292:2243–2248.
31.
KennyAM, BoxerRS, KleppingerA, BrindisiJ, FeinnR, BurlesonJA. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J Am Geriatr Soc, 2010; 58:1707–1714.
32.
JedrzejukD, MedrasM, MilewiczA, DemissieM. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: Effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male, 2003; 6:151–156.
33.
CalliesF, FassnachtM, van VlijmenJC, KoehlerI, HueblerD, SeibelMJ, ArltW, AllolioB. Dehydroepiandrosterone replacement in women with adrenal insufficiency: Effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab, 2001; 86:1968–1972.
PercheronG, HogrelJY, Denot-LedunoisS, FayetG, ForetteF, BaulieuEE, FardeauM, MariniJF. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: A double-blind placebo-controlled trial. Arch Int Med, 2003; 163:720–727.
36.
IgwebuikeA, IrvingBA, BigelowML, ShortKR, McConnellJP, NairKS. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. J Clin Endocrinol Metab, 2008; 93:534–538.
37.
RizzoliR. Management of the oldest old with osteoporosis. Eur Geriatr Med, 2010; 1:15–21.
38.
NawataH, TanakaS, TanakaS, TakayanagiR, SakaiY, YanaseT, IkuyamaS, HajiM. Aromatase in bone cell: Association with osteoporosis in postmenopausal women. J Steroid Biochem Mol Biol, 1995; 53:165–174.
39.
WangL, WangYD, WangWJ, ZhuY, LiDJ. Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J Mol Endocrinol, 2007; 38:467–479.
40.
ClarkeBL, EbelingPR, JonesJD, WahnerHW, O'FallonWM, RiggsBL, FitzpatrickLA. Predictors of bone mineral density in aging healthy men varies by skeletal site. Calcified Tiss Int, 2002; 70:137–145.
41.
WeissEP, ShahK, FontanaL, LambertCP, HolloszyJO, VillarealDT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr, 2009; 89:1459–1467.
42.
von MuhlenD, LaughlinGA, Kritz-SilversteinD, BergstromJ, BettencourtR. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: The DAWN trial. Osteoporosis Int, 2008; 19:699–707.
43.
JankowskiCM, GozanskyWS, KittelsonJM, Van PeltRE, SchwartzRS, KohrtWM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab, 2008; 93:4767–4773.
44.
JankowskiCM, GozanskyWS, SchwartzRS, DahlDJ, KittelsonJM, ScottSM, Van PeltRE, KohrtWM. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: A randomized, controlled trial. J Clin Endocrinol Metab, 2006; 91:2986–2993.
45.
LabrieF, DiamondP, CusanL, GomezJL, BelangerA, CandasB. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab, 1997; 82:3498–3505.
46.
SunY, MaoM, SunL, FengY, YangJ, ShenP. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. Chinese Med J, 2002; 115:402–404.
47.
NairKS, RizzaRA, O'BrienPet al.DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med, 2006; 355:1647–1659.
48.
BerrC, WancataJ, RitchieK. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol, 2005; 15:463–471.
49.
GrahamJE, RockwoodK, BeattieBL, EastwoodR, GauthierS, TuokkoH, McDowellI. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet, 1997; 349:1793–1796.
50.
BarnesDE, YaffeK. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol, 2011; 10:819–828.
51.
LautenschlagerNT, CoxK, CyartoEV. The influence of exercise on brain aging and dementia. Biochim Biophys Acta, 2012; 1822:474–481.
SuzukiM, WrightLS, MarwahP, LardyHA, SvendsenCN. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA, 2004; 101:3202–3207.
54.
LangPO, LapennaA, PittsD, AspinallR. Immunological pathogenesis of main age-related diseases and frailty: Role of immunosenescence. Eur Ger Med, 2010; 1:112–121.
55.
DavisSR, ShahSM, McKenzieDP, KulkarniJ, DavisonSL, BellRJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab, 2008; 93:801–808.
56.
ValentiG, FerrucciL, LauretaniF, CeresiniG, BandinelliS, LuciM, CedaG, MaggioM, SchwartzRS. Dehydroepiandrosterone sulfate and cognitive function in the elderly: The InCHIANTI Study. J Endocrinol Invest, 2009; 32:766–772.
57.
MorrisonMF, RedeiE, TenHaveT, ParmeleeP, BoyceAA, SinhaPS, KatzIR. Dehydroepiandrosterone sulfate and psychiatric measures in a frail, elderly residential care population. Biol Psychiatry, 2000; 47:144–150.
58.
Barrett-ConnorE, EdelsteinSL. A prospective study of dehydroepiandrosterone sulfate and cognitive function in an older population: The Rancho Bernardo Study. J Am Geriatr Soc, 1994; 42:420–423.
59.
Kritz-SilversteinD, von MuhlenD, LaughlinGA, BettencourtR. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: The DHEA and Well-Ness (DAWN) Trial. J Am Geriatr Soc, 2008; 56:1292–1298.
60.
van NiekerkJK, HuppertFA, HerbertJ. Salivary cortisol and DHEA: Association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology, 2001; 26:591–612.
61.
BarnhartKT, FreemanE, GrissoJA, RaderDJ, SammelM, KapoorS, NestlerJE. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab, 1999; 84:3896–3902.
62.
FinckhA, BernerIC, Aubry-RozierB, SoAK. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol, 2005; 32:1336–1340.
63.
WolfOT, KudielkaBM, HellhammerDH, HellhammerJ, KirschbaumC. Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor. Psychoneuroendocrinology, 1998; 23:617–629.
64.
YamadaS, AkishitaM, FukaiS, OgawaS, YamaguchiK, MatsuyamaJ, KozakiK, TobaK, OuchiY. Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment. Geriatr Gerontol Int, 2010; 10:280–287.
65.
SamarasN, RossiG, GiannakopoulosP, GoldG. Vascular depression. An age-related mood disorder. Eur Ger Med, 2010; 4:220–225.
66.
SteffensDC. A multiplicity of approaches to characterize geriatric depression and its outcomes. Curr Opin Psychiatry, 2009; 22:522–526.
67.
RobichaudM, DebonnelG. Modulation of the firing activity of female dorsal raphe nucleus serotonergic neurons by neuroactive steroids. J Endocrinol, 2004; 182:11–21.
68.
Barrett-ConnorE, von MuhlenD, LaughlinGA, KripkeA. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: The Rancho Bernardo Study. J Am Geriatr Soc, 1999; 47:685–691.
69.
MichaelA, JenawayA, PaykelES, HerbertJ. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry, 2000; 48:989–995.
70.
SchmidtPJ, DalyRC, BlochM, SmithMJ, DanaceauMA, St ClairLS, MurphyJH, HaqN, RubinowDR. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry, 2005; 62:154–162.
WolkowitzOM, ReusVI, KeeblerAet al.Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry, 1999; 156:646–649.
73.
StrousRD, MaayanR, LapidusR, StryjerR, LustigM, KotlerM, WeizmanA. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry, 2003; 60:133–141.
SamarasN, ChevalleyT, SamarasD, GoldG. Older patients in the emergency department: A review. Ann Emerg Med, 2010; 56:261–269.
76.
SrinivasanM, IrvingBA, DhatariyaK, KlausKA, HartmanSJ, McConnellJP, NairKS. Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women. J Clin Endocrinol Metab, 2009; 94:761–764.
77.
RiceSP, AgarwalN, BolusaniH, NewcombeR, ScanlonMF, LudgateM, ReesDA. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: A randomized crossover trial. J Clin Endocrinol Metab, 2009; 94:1966–1972.
DiamondP, CusanL, GomezJL, BelangerA, LabrieF. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol, 1996; 150,Suppl:S43–S50.
80.
SrinivasanM, IrvingBA, FryeRL, O'BrienP, HartmanSJ, McConnellJP, NairKS. Effects on lipoprotein particles of long-term dehydroepiandrosterone in elderly men and women and testosterone in elderly men. J Clin Endocrinol Metab, 2010; 95:1617–1625.
BellRJ, DavisonSL, PapaliaMA, McKenzieDP, DavisSR. Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause, 2007; 14:630–638.
83.
ShufeltC, BretskyP, AlmeidaCM, JohnsonBD, ShawLJ, AzzizR, BraunsteinGD, PepineCJ, BittnerV, VidoDA, StanczykFZ, Bairey MerzCN. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: Results from the National Institutes of Health–National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE)J Clin Endocrinol Metab, 2010; 95:4985–4992.
84.
ChristiansenJJ, AndersenNH, SørensenKE, PedersenEM, BennettP, AndersenM, ChristiansenJS, JørgensenJO, GravholtCH. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clin Endocrinol, 2007; 66:426–433.
85.
PanjariM, BellRJ, JaneF, AdamsJ, MorrowC, DavisSR. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas, 2009; 63:240–245.
86.
ClearyMP, ZiskJF. Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes, 1986; 10:193–204.
87.
MohanPF, IhnenJS, LevinBE, ClearyMP. Effects of dehydroepiandrosterone treatment in rats with diet-induced obesity. J Nutr, 1990; 120:1103–1114.
88.
HansenPA, HanDH, NolteLA, ChenM, HolloszyJO. DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet. Am J Physiol, 1997; 273:R1704–R1708.
89.
GoldenSH, DobsAS, VaidyaD, SzkloM, GapsturS, KoppP, LiuK, OuyangP. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab, 2007; 92:1289–1295.
90.
Barrett-ConnorE, FerraraA. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: The Rancho Bernardo Study. J Clin Endocrinol Metab, 1996; 81:59–64.
91.
DhatariyaK, BigelowML, NairKS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes, 2005; 54:765–769.
92.
Gebre-MedhinG, HusebyeES, MallminH, HelströmL, BerneC, KarlssonFA, KämpeO. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clin Endocrinol, 2000; 52:775–780.
93.
HayashiT, EsakiT, MutoE, KanoH, AsaiY, ThakurNK, SumiD, JayachandranM, IguchiA. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: The possible role of nitric oxide. Arterioscler Thromb Vasc Biol, 2000; 20:782–792.
94.
GordonGB, BushDE, WeismanHF. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest, 1988; 82:712–720.
95.
WangL, HaoQ, WangYD, WangWJ, LiDJ. Protective effects of dehydroepiandrosterone on atherosclerosis in ovariectomized rabbits via alleviating inflammatory injury in endothelial cells. Atherosclerosis, 2011; 214:47–57.
96.
EichDM, NestlerJE, JohnsonDE, DworkinGH, KoD, WechslerAS, HessML. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation, 1993; 87:261–269.
97.
SamarasN, SamarasD, LangPO, ForsterA, PichardC, FrangosE, MeyerP. A view of geriatrics through hormonesWhat is the relation between andropause and well-known geriatric syndromes? Maturitas. 2013; 74:213–219.
98.
FeldmanHA, JohannesCB, AraujoAB, MohrBA, LongcopeC, McKinlayJB. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: Prospective results from the Massachusetts Male Aging Study. Am J Epidemiol, 2001; 153:79–89.
99.
YoshidaS, AiharaK, AzumaH, UemotoR, Sumitomo-UedaY, YagiS, IkedaY, IwaseT, NishioS, KawanoH, MikiJ, YamadaH, HirataY, AkaikeM, SataM, MatsumotoT. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis, 2010; 212:310–315.
100.
HerringtonDM. Dehydroepiandrosterone and coronary atherosclerosis. Ann NY Acad Sci, 1995; 774:271–280.
NakamuraS, YoshimuraM, NakayamaM, ItoT, MizunoY, HaradaE, SakamotoT, SaitoY, NakaoK, YasueH, OgawaH. Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation, 2004; 110:1787–1793.
103.
JankowskaEA, BielB, MajdaJ, SzklarskaA, LopuszanskaM, MedrasM, AnkerSD, BanasiakW, Poole-WilsonPA, PonikowskiP. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation, 2006; 114:1829–1837.
104.
Barrett-ConnorE, Goodman-GruenD. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation, 1995; 91:1757–1760.
105.
Barrett-ConnorE, KhawKT, YenSS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med, 1986; 315:1519–1524.
106.
HydeZ, FlickerL, HankeyGJ, AlmeidaOP, McCaulKA, ChubbSA, YeapBB. Prevalence and predictors of sexual problems in men aged 75–95 years: A population-based study. J Sex Med, 2012; 9:442–453.
107.
BasarMM, AydinG, MertHC, KelesI, CaglayanO, OrkunS, BatislamE. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology, 2005; 66:597–601.
108.
AlexopoulouO, JamartJ, MaiterD, HermansMP, De HertoghR, De NayerP, BuysschaertM. Erectile dysfunction and lower androgenicity in type 1 diabetic patients. Diabetes Metab, 2001; 27:329–336.
109.
FeldmanHA, GoldsteinI, HatzichristouDG, KraneRJ, McKinlayJB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol, 1994; 151:54–61.
110.
ReiterWJ, PychaA, SchatzlG, KlinglerHC, MärkI, AuterithA, MarbergerM. Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction. Urology, 2000; 55:755–758.
111.
ReiterWJ, PychaA, SchatzlG, PokornyA, GruberDM, HuberJC, MarbergerM. Dehydroepiandrosterone in the treatment of erectile dysfunction: A prospective, double-blind, randomized, placebo-controlled study. Urology, 1999; 53:590–594.
112.
MoralesA, BlackA, EmersonL, BarkinJ, KuzmarovI, DayA. Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male, 2009; 12:104–112.
113.
ReiterWJ, SchatzlG, MarkI, ZeinerA, PychaA, MarbergerM. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res, 2001; 29:278–281.
114.
DavisSR, DavisonSL, DonathS, BellRJ. Circulating androgen levels and self-reported sexual function in women. JAMA, 2005; 294:91–96.
115.
GenazzaniAR, StomatiM, ValentinoV, PluchinoN, PotE, CasarosaE, MerliniS, GianniniA, LuisiM. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric, 2011; 14:661–668.
116.
ArltW, CalliesF, van VlijmenJC, KoehlerI, ReinckeM, BidlingmaierM, HueblerD, OettelM, ErnstM, SchulteHM, AllolioB. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med, 1999; 341:1013–1020.
117.
MunarrizR, TalakoubL, FlahertyE, GioiaM, HoagL, KimNN, TraishA, GoldsteinI, GuayA, SparkR. Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: Androgen and questionnaire results. J Sex Marital Ther, 2002; 28,Suppl 1:165–173.
118.
LabrieF, ArcherD, BouchardC, FortierM, CusanL, GomezJL, GirardG, BaronM, AyotteN, MoreauM, DubéR, CôtéI, LabrieC, LavoieL, BergerL, GilbertL, MartelC, BalserJ. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause, 2009; 16:923–931.
119.
PanjariM, BellRJ, JaneF, WolfeR, AdamsJ, MorrowC, DavisSR. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med, 2009; 6:2579–2590.
120.
StomatiM, MonteleoneP, CasarosaE, QuiriciB, PuccettiS, BernardiF, GenazzaniAD, RovatiL, LuisiM, GenazzaniAR. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecolog Endocrinol, 2000; 14:342–363.
LabrieF, Luu-TheV, BélangerA, LinSX, SimardJ, PelletierG, LabrieC. Is dehydroepiandrosterone a hormone?J Endocrinol, 2005; 187:169–196.
123.
ArltW. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab, 2009; 94:1059–1067.
124.
LabrieF, CusanL, GomezJL, MartelC, BérubéR, BélangerP, ChaussadeV, DelocheC, LeclaireJ. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol, 2008; 110:1–9.
125.
SulcováJ, HillM, HamplR, MasekZ, NovácekA, CeskaR, StárkaL. Effects of transdermal application of DHEA on the levels of steroids, gonadotropins and lipids in men. Physiol Res, 2000; 49:685–693.
126.
ArnoldJT. DHEA metabolism in prostate: For better or worse?Mol Cell Endocrinol, 2009; 301:83–88.
127.
StanwaySJ, PurohitA, WooLW, SufiS, VigushinD, WardR, WilsonRH, StanczykFZ, DobbsN, KulinskayaE, ElliottM, PotterBV, ReedMJ, CoombesRC. Phase I study of STX 64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clin Cancer Res, 2006; 12:1585–1592.
128.
SchwartzAG, PashkoLL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev, 2004; 3:171–187.
129.
SchwartzAG, PashkoLL. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cell Biochem Supplement, 1995; 22:210–217.
